Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 1, 2014, Pages 12-17

  Meredith, Ruby F ^a   Torgue, Julien ^b   Azure, Michael T ^c   Shen, Sui ^a   Saddekni, Souheil ^c   Banaga, Eileen ^b   Carlise, Ronda ^d   Bunch, Patty ^d   Yoder, Daniel ^c   Alvarez, Ronald ^d  

^a The University of Alabama at Birmingham   (United States)

^b AREVA NP   (France)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

212Pb TCMC trastuzumab; Antibody immunotherapy; Cancer; Intraperitoneal; Ovarian

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; FUROSEMIDE; GEMCITABINE; LEAD 212; RADIOPHARMACEUTICAL AGENT; SPIRONOLACTONE; TAXANE DERIVATIVE; TCMC TRASTUZUMAB PB 212; TRASTUZUMAB; UNCLASSIFIED DRUG; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZA 1,4,7,10 TETRA (2 CARBAMOYLMETHYL)CYCLODODECANE; 2-(4-ISOTHIOCYANATOBENZYL)-1,4,7,10--TETRAAZA-1,4,7,10-TETRA-(2-CARBAMOYLMETHYL)CYCLODODECANE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; ISOTHIOCYANIC ACID DERIVATIVE; LEAD; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CASE REPORT; CYTOREDUCTIVE SURGERY; DOSIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GAMMA CAMERA; HUMAN; MAXIMUM PERMISSIBLE DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT MONITORING; PERITONEAL CAVITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOACTIVITY; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; URINARY EXCRETION; VERY ELDERLY; BIOSYNTHESIS; COHORT ANALYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY TUMOR; SCINTISCANNING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; INJECTIONS, INTRAPERITONEAL; ISOTHIOCYANATES; LEAD RADIOISOTOPES; MIDDLE AGED; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2;

EID: 84890532810     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1531     Document Type: Article

References (32)

1. Verheijen RH, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24:571.
2. Armstrong DK, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34.
3. Macey DJ, Meredith RF. A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy. Clin Cancer Res 1999;5:3044s.
4. Sgouros G, et al. MIRD Pamphlet No. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010;51:311.
5. Young RC. Initial therapy for early ovarian carcinoma. Cancer 1987;60:2042.
6. Jacobs AJ, et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 1993;82:586.
7. Hird V, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68:403.
8. Epenetos AA, et al. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 2000;10:44.
9. Rosenblum MG, et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 1999;5:953.
10. Meredith R, et al. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. Cancer Biother Radiopharm 2012;27:36.
11. Macklis RM, et al. Alpha particle radio-immunotherapy: Animal models and clinical prospects. Int J Radiat Oncol Biol Phys 1989;16:1377.
12. Jurcic J. Phase I trial of the targeted alpha-particle nanogenerator actinium-225 (225Ac)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML). Blood 2011; 118:768.
13. Milenic DE, et al. Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007; 13:1926.
14. Milenic DE, et al. Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 2008;14:5108.
15. Milenic DE, et al. Improved efficacy of alpha-particletargeted radiation therapy: Dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 2010;116:1059.
16. Azure M. Radiolabeling and imaging of 212Pb-TCMCtrastuzumab. World Molecular Imaging Congress, Kyoto, Japan, 2010.
17. Yong KJ, et al. Sensitization of tumor to (212)Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int J Radiat Oncol Biol Phys 2013;85:1119.
18. Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687.
19. Tan Z, et al. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol 2012;40:1881.
20. Andersson H, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of (211)At-MX35 F(ab)2-a phase I study. J Nucl Med 2009;50:1153.
21. Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I/II study. Gynecol Oncol 1997;65:94.
22. Alvarez RD, et al. A phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806.
23. Elgqvist J. Targeted alpha therapy: Part I. Curr Radiopharm 2011;4:176.
24. Baidoo KE, et al. Molecular pathways: Targeted alphaparticle radiation therapy. Clin Cancer Res 2013;19:530.
25. Horak E, et al. Radioimmunotherapy targeting of HER2/ neu oncoprotein on ovarian tumor using lead-212-DOTAAE1. J Nucl Med 1997;38:1944.
26. Song EY, et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther 2008;7:76.
27. Palm S, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 2007;69:572.
28. Elgqvist J, et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 2006;47:1342.
29. Elgqvist J, et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother Radiopharm 2009;24:509.
30. Elgqvist J, et al. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice. J Oncol 2010;2010:394913.
31. Borchardt PE, et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084.
32. Gustafsson AM, et al. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. NuclMed Biol 2012;39:15.